On June 23, 2026, ACTAVIS ELIZABETH received FDA approval for generic version ANDA #203611, a move which positions the manufacturer to capitalize on market opportunities in the relevant therapeutic class. This approval allows ACTAVIS to expand its portfolio while potentially pressuring branded competitors and increasing its foothold in the generic supply chain.